Shanghai Henlius Biotech, Inc. (HKG:2696)

Shanghai Henlius Biotech Revenue

Shanghai Henlius Biotech had revenue of 3.59B CNY in the half year ending June 30, 2026, with 30.67% growth. This brings the company's revenue in the last twelve months to 7.44B, up 28.24% year-over-year. In the year 2025, Shanghai Henlius Biotech had annual revenue of 6.67B with 16.46% growth.

• Revenue (ttm): 7.44B CNY
• Revenue Growth: +28.24%
• P/S Ratio: 4.25
• Revenue / Employee: 1.82M CNY
• Employees: 4,082
• Market Cap: 36.52B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	6.67B	942.18M	16.46%
Dec 31, 2024	5.72B	329.54M	6.11%
Dec 31, 2023	5.39B	2.18B	67.82%
Dec 31, 2022	3.21B	1.53B	91.07%
Dec 31, 2021	1.68B	1.09B	186.34%

Data Source: S&P Global Market Intelligence Last updated: Aug 21, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 10, 2026

Data Sources Report a data error